Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Source MDx, a molecular diagnostics development company, has announced a partnership with Brigham and Women's Hospital in Boston to examine RNA-based biomarkers in multiple sclerosis patients and healthy control participants unaffected by the disease.
Subscribe to our email newsletter
The goal of the study is to identify diagnostic markers and to determine markers of active disease (relapses) or stable disease, along with response markers for currently available multiple sclerosis (MS) therapies. The study will utilize Source MDx’s patented gene expression profiling for the identification and monitoring of MS.
Phil De Jager, assistant professor in the department of neurology at Brigham and Women’s Hospital, said: “Our objective is to evaluate RNA-based markers in the broader context of each patient’s genetics, protein markers, family history and clinical information in order to determine markers that can help in making a diagnosis of MS and prognosticate on drug response in MS. By doing so, we hope to be better able to identify markers that could lead to improved diagnostic tools, therapies or treatment regimen.”
Karl Wassmann, CEO of Source MDx, said: “We look forward to working with Brigham and Women’s Hospital and furthering our ongoing research in biomarkers associated with inflammatory disease in general and MS specifically. We believe this research will ultimately lead to improved, more targeted treatments for patients.”